Results 271 to 280 of about 62,786 (347)

Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias: A Meta-Analysis of 38 Randomized Controlled Trials. [PDF]

JACC Adv
Jaiswal V, Ang SP, Kumar D, Deb N, Jaiswal A, Joshi A, Nasir YM, Bandyopadhyay D, Michos ED, Benjamin EJ, Fonarow GC.   +10 more
europepmc   +1 more source

Semaglutide Adherence and Cardiovascular Diseases in Patients With Type 2 Diabetes: Evidence From Real-World Data in Japan. [PDF]

Cureus
Masudo C, Horii T, Suzuki R, Mihara K.
europepmc   +1 more source

Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches

PROTEOMICS, EarlyView.
Paul Perco, Matthias Ley, Kinga Kęska‐Izworska, Dorota Wojenska, Enrico Bono, Samuel M. Walter, Lucas Fillinger, Klaus Kratochwill   +7 more
wiley   +1 more source

Ibuprofen inhibits human sweet taste and glucose detection implicating an additional mechanism of metabolic disease risk reduction

British Journal of Pharmacology, EarlyView.
Background and Purpose The human sweet taste receptor, TAS1R2–TAS1R3, conveys sweet taste in the mouth and may help regulate glucose metabolism throughout the body. Ibuprofen and naproxen are structurally similar to known inhibitors of TAS1R2–TAS1R3 and have been associated with metabolic benefits.
Emily C. Hanselman, Caroline P. Harmon, Daiyong Deng, Sarah M. Sywanycz, Lauren Caronia, Peihua Jiang, Paul A. S. Breslin   +6 more
wiley   +1 more source

The effect of empagliflozin and sitagliptin as an add-on therapy to metformin in blood pressure reduction in diabetic patients in primary health care settings in Riyadh, Saudi Arabia. [PDF]

J Family Med Prim Care
Ahmed M, Altoyan M, Hijazi R, AlJebreen J, Alshalan MH, Aldhalaan R, Altarifi L.   +6 more
europepmc   +1 more source

Obesity‐related glomerulopathy: How it happens and future perspectives

Diabetic Medicine, EarlyView.
Abstract Obesity‐related glomerulopathy (ORG) is an emerging complication of excess adiposity. Its incidence rises alongside the obesity pandemic. Up to 40% of individuals can be affected by ORG, irrespective of the status of glomerular filtration rate and albuminuria.
Jian‐Wen Samuel Lee‐Boey, Jia‐Kai Tan, Zhan‐Foong Lim, Francesco Zaccardi, Kamlesh Khunti, Majid Ezzati, Edward W. Gregg, Lee‐Ling Lim   +7 more
wiley   +1 more source

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor- and Metformin-Associated Euglycemic Diabetic Ketoacidosis and Lactic Acidosis Leading to Refractory Acute Kidney Injury: Successful Management With Hemodialysis. [PDF]

Cureus
Yoshida N, Tanaka T, Suzuki Y, Sakurai H, Takahashi S, Hitaka M, Ishii S, Okuda J, Yamazaki K, Ohashi Y.   +9 more
europepmc   +1 more source

The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction

Diabetic Medicine, EarlyView.
Abstract Aims Following an acute myocardial infarction (AMI), individuals with type 2 diabetes (T2DM) have a 2‐to‐3 fold increased risk of mortality compared to those without diabetes, and globally cardiorenal complications account for 50% of diabetes‐related deaths.
M. U. Shah, C. L. Cliff, P. E. Squires, K. Lee, C. E. Hills   +4 more
wiley   +1 more source

Section 16: Diabetes Care in the Hospital. [PDF]

Clin Diabetes
europepmc   +1 more source

Factors influencing early renal function changes after SGLT2 inhibitors use and its long-term prognosis: a real-world retrospective study. [PDF]

Ren Fail
Xie B, Ye N, Wang G, Cheng H.
europepmc   +1 more source